Adavosertib (AZD1775, MK-1775): Mechanism of Action

Adavosertib (AZD1775, MK-1775) MOA:Targeting WEE1/Cell Cycle Checkpoint Pathway for Ovarian Cancer

🎯 check Adavosertib (AZD1775, MK-1775) product page

Adavosertib is a potent, selective ATP-competitive Wee1 inhibitor. It affects cell cycle and DNA damage response signaling by reducing CDK1 phosphorylation and abrogating the G2/M checkpoint, effectively inhibiting tumor cell proliferation and promoting apoptosis.

Primary Applications and Mechanism of Action